211 related articles for article (PubMed ID: 31735550)
21. Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin.
Jacquemont C; Simon JA; D'Andrea AD; Taniguchi T
Mol Cancer; 2012 Apr; 11():26. PubMed ID: 22537224
[TBL] [Abstract][Full Text] [Related]
22. MEN1 and FANCD2 mediate distinct mechanisms of DNA crosslink repair.
Marek LR; Kottemann MC; Glazer PM; Bale AE
DNA Repair (Amst); 2008 Mar; 7(3):476-86. PubMed ID: 18258493
[TBL] [Abstract][Full Text] [Related]
23. FANCD2 depletion sensitizes cancer cells repopulation ability in vitro.
Lyakhovich A; Surralles J
Cancer Lett; 2007 Oct; 256(2):186-95. PubMed ID: 17643815
[TBL] [Abstract][Full Text] [Related]
24. Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma.
Turner JG; Cui Y; Bauer AA; Dawson JL; Gomez JA; Kim J; Cubitt CL; Nishihori T; Dalton WS; Sullivan DM
Cancer Res; 2020 Dec; 80(23):5344-5354. PubMed ID: 33023948
[TBL] [Abstract][Full Text] [Related]
25. FANCD2 deficiency sensitizes SHH medulloblastoma to radiotherapy via ferroptosis.
Zhou H; Wang YX; Wu M; Lan X; Xiang D; Cai R; Ma Q; Miao J; Fang X; Wang J; Luo D; He Z; Cui Y; Liang P; Wang Y; Bian XW
J Pathol; 2024 Apr; 262(4):427-440. PubMed ID: 38229567
[TBL] [Abstract][Full Text] [Related]
26. FANCD2 promotes the malignant behavior of endometrial cancer cells and its prognostic value.
Zheng C; Ren Z; Chen H; Yuan X; Suye S; Yin H; Zhou Z; Fu C
Exp Cell Res; 2022 Dec; 421(2):113388. PubMed ID: 36257352
[TBL] [Abstract][Full Text] [Related]
27. Cells Deficient in the Fanconi Anemia Protein FANCD2 are Hypersensitive to the Cytotoxicity and DNA Damage Induced by Coffee and Caffeic Acid.
Burgos-Morón E; Calderón-Montaño JM; Orta ML; Guillén-Mancina E; Mateos S; López-Lázaro M
Toxins (Basel); 2016 Jul; 8(7):. PubMed ID: 27399778
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin.
Poore B; Yuan M; Arnold A; Price A; Alt J; Rubens JA; Slusher BS; Eberhart CG; Raabe EH
Neuro Oncol; 2019 Feb; 21(2):252-263. PubMed ID: 30239952
[TBL] [Abstract][Full Text] [Related]
29. MTDH/AEG-1 downregulation using pristimerin-loaded nanoparticles inhibits Fanconi anemia proteins and increases sensitivity to platinum-based chemotherapy.
Bi J; Areecheewakul S; Li Y; Yang S; Zhang Y; Ebeid K; Li L; Thiel KW; Zhang J; Dai D; Salem AK; Leslie KK; Meng X
Gynecol Oncol; 2019 Nov; 155(2):349-358. PubMed ID: 31477281
[TBL] [Abstract][Full Text] [Related]
30. In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma.
Veringa SJ; Biesmans D; van Vuurden DG; Jansen MH; Wedekind LE; Horsman I; Wesseling P; Vandertop WP; Noske DP; Kaspers GJ; Hulleman E
PLoS One; 2013; 8(4):e61512. PubMed ID: 23637844
[TBL] [Abstract][Full Text] [Related]
31. FANCD2 knockdown with shRNA interference enhances the ionizing radiation sensitivity of nasopharyngeal carcinoma CNE-2 cells.
Bao Y; Feng H; Zhao F; Zhang L; Xu S; Zhang C; Zhao C; Qin G
Neoplasma; 2021 Jan; 68(1):40-52. PubMed ID: 32940045
[TBL] [Abstract][Full Text] [Related]
32. Involvement of Fanconi anemia genes FANCD2 and FANCF in the molecular basis of drug resistance in leukemia.
Yao C; Du W; Chen H; Xiao S; Huang L; Chen FP
Mol Med Rep; 2015 Jun; 11(6):4605-10. PubMed ID: 25647473
[TBL] [Abstract][Full Text] [Related]
33. FANCD2 binds CtIP and regulates DNA-end resection during DNA interstrand crosslink repair.
Unno J; Itaya A; Taoka M; Sato K; Tomida J; Sakai W; Sugasawa K; Ishiai M; Ikura T; Isobe T; Kurumizaka H; Takata M
Cell Rep; 2014 May; 7(4):1039-47. PubMed ID: 24794430
[TBL] [Abstract][Full Text] [Related]
34. High-risk human papillomavirus oncogenes disrupt the Fanconi anemia DNA repair pathway by impairing localization and de-ubiquitination of FancD2.
Khanal S; Galloway DA
PLoS Pathog; 2019 Feb; 15(2):e1007442. PubMed ID: 30818369
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenomic approach reveals a role for the x(c)- cystine/glutamate antiporter in growth and celastrol resistance of glioma cell lines.
Pham AN; Blower PE; Alvarado O; Ravula R; Gout PW; Huang Y
J Pharmacol Exp Ther; 2010 Mar; 332(3):949-58. PubMed ID: 20007406
[TBL] [Abstract][Full Text] [Related]
36. Identification of arnicolide C as a novel chemosensitizer to suppress mTOR/E2F1/FANCD2 axis in non-small cell lung cancer.
Chen YF; Pang YC; Wang HC; Wu PE; Chen ZJ; Huang D; Peng DL; Yan YM; Liu C; Wu LC; Fan XZ; Cheng YX; Liu YQ
Br J Pharmacol; 2024 Apr; 181(8):1221-1237. PubMed ID: 37926864
[TBL] [Abstract][Full Text] [Related]
37. FANCD2 influences replication fork processes and genome stability in response to clustered DSBs.
Zhu J; Su F; Mukherjee S; Mori E; Hu B; Asaithamby A
Cell Cycle; 2015; 14(12):1809-22. PubMed ID: 26083937
[TBL] [Abstract][Full Text] [Related]
38. Drosophila homologs of FANCD2 and FANCL function in DNA repair.
Marek LR; Bale AE
DNA Repair (Amst); 2006 Nov; 5(11):1317-26. PubMed ID: 16860002
[TBL] [Abstract][Full Text] [Related]
39. Preparation, characterization, and assessment of the antiglioma effects of liposomal celastrol.
Huang Y; Zhou D; Hang T; Wu Z; Liu J; Xu Q; Xie X; Zuo J; Wang Z; Zhou Y
Anticancer Drugs; 2012 Jun; 23(5):515-24. PubMed ID: 22343423
[TBL] [Abstract][Full Text] [Related]
40. FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons.
Kachnic LA; Li L; Fournier L; Ferraiolo N; Dahm-Daphi J; Borgmann K; Willers H
Cancer Lett; 2011 Jun; 305(1):86-93. PubMed ID: 21414716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
